

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(file as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/714,591
		Filing Date	November 14, 2003
		First Named Inventor	RAMACHANDRAN, JANAKIRAMAN
		Art Unit	1616
Sheet <b>1</b> of <b>3</b>		Examiner Name	Not yet assigned
		Attorney Docket Number	GANG-006

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
NK		US-	4,957,686	09/18/1990	Norris	
↓		US-	5,688,501	11/18/1997	Merril, et al.	
		US-	6,121,036	12/19/2000	Ghanbari, et al.	
		US-	6,264,945	07/24/2001	Fischetti et al.	
NK		US2002/005802		05/16/2002	Nelson et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
NK		WO 95/31562	11/23/1995	Quest International B.V.		
↓		WO 95/27043	10/12/1995	Exponential Biotherapies, Inc.		
		WO 01/82945	11/8/2001	New Horizons Diagnostic Corporation		
		GB 829266 A	03/02/1960			
NK		EP 0403292 A2	06/14/1990	Microbial Development Limited		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NK		Blasi et al. "Two beginnings for a single purpose: the dual-start holins in the regulation of phage lysis" Mol Microbiol. 1996 Aug;21(4):675-82	
NK		Blasi et al. "The C-terminal sequence of the lambda holin constitutes a cytoplasmic regulatory domain." J Bacteriol. 1999 May;181(9):2922-9	

Examiner Signature	/Nicole Kinsey/	Date Considered	10/03/2006
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1448A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(fill in as many checks as are necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/714,591		
		Filing Date	November 14, 2003		
		First Named Inventor	RAMACHANDRAN, JANAKIRAMAN		
		Art Unit	1616		
		Examiner Name	Not yet assigned		
Sheet	2	of	3	Attorney Docket Number	GANG-006

NK		Carlton, "Phage therapy: past history and future prospects", R. M., Arch. Immunol. Ther. Exp., 47, 267(1999)	
		Dressman et al. "Lysis and lysis inhibition in bacteriophage T4: rV mutations reside in the holin t gene" J Bacteriol. 1999 Jul;181(14):4391-6	
		Grundling et al. "Holins kill without warning" Proc. Natl. Acad. Sci. USA 98:9348-52 (2001)	
		Hori et al "Construction of self-disruptive <i>Bacillus megaterium</i> in response to substrate exhaustion for polyhydroxybutyrate production", Appl Microbio. Biotech 2002 59 211-216	
		Johnson-Boaz et al. "A dominant mutation in the bacteriophage lambda S gene causes premature lysis and an absolute defective plating phenotype", Mol Microbiol. 1994 Aug;13(3):495-504	
		Jain et al. "Use of lambda phage s and r gene products in an inducible lysis system for <i>vibrio cholerae</i> - and <i>salmonella enterica</i> serovar typhimurium-based DNA vaccine delivery systems", Infect Immun, 68, 986-89 (2000).	
		Kutter, "Bacteriophage Therapy," at <a href="http://www.evergreen.edu/phage/phagetherapy/phagetherapy.html">www.evergreen.edu/phage/phagetherapy/phagetherapy.html</a> , last updated 07/14/2004	
		Merrill et al "Long-circulating bacteriophage as antibacterial agents", (Proc. Natl. Acad. Sci. USA 93, 3188 (1996)	
		Miller et al. "Bacteriophage T4 genome", Microbiol Mol Biol Rev. (2003) 67(1):86-156	
		Martin et al. "Functional analysis of the two-gene lysis system of the Pneumococcal phage Cp-I in homologous and heterologous host cells" J. Bacteriol. 180:210-7 (1998)	
↓		Ramanculov et al. "Functional analysis of the phage T4 holin in a lambda context," Mol. Genet. Genomics 265:345-53 (2001)	
NK		Ramanculov et al. "Genetic analysis of the T4 holin: timing and topology" Gene 265:25-36 (2001)	

Examiner Signature	/Nicole Kinsey/	Date Considered	10/03/2006
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
		Application Number	10714,591
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Filing Date	November 14, 2003
		First Named Inventor	RAMACHANDRAN, JANAKIRAMAN
		Art Unit	1816
		Examiner Name	Not yet assigned
		Attorney Docket Number	GANG-008
Sheet	3	of	3

NK		Sulakvelidze et al. "Minireview Bacteriophage Therapy", Antimicrob Agents Chemotherap, vol. 45, no. 3, pg. 649-659 (2001)	
		Sanders et al "A chloride-inducible gene expression cassette and its use in induced lysis of <i>lactococcus lactis</i> ", Appl Environ. Microbiol. 1997 63 4877-82	
		Smith et al. "Purification and biochemical characterization of the lambda holin" J Bacteriol. 1998 May;180(9):2531-40	
		Tan et al. "Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile." J Med Microbiol. 2001 Jul;50(7):613-9	
		Vukov et al. "Functional analysis of heterologous holin proteins in a lambdaDeltaS genetic background." FEMS Microbiol Lett. 2000 Mar 15;184(2):179-86;	
		Wang et al. "Holins: the protein clocks of bacteriophage infections." Annu Rev Microbiol. 2000;54:799-825	
NK		Young, "Bacteriophage holins: deadly diversity." J Mol Microbiol Biotechnol. 2002 Jan;4(1):21-36	


Examiner Signature	/Nicole Kinsey/	Date Considered	10/03/2006
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/714,591
		Filing Date	November 14, 2003
		First Named Inventor	RAMACHANDRAN, JANAKIRAMAN
		Art Unit	1616
Sheet 1 of 2		Examiner Name	Not yet assigned
		Attorney Docket Number	GANG-006

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NK		Eaton et al. "Bacteriophage therapy", (1934). Bacteriophage Therapy. JAMA 103:1769-1776; 1847-1853, 1934-1939	
NK		Slopek et al. "Immunogenic effect of bacteriophage in patients subjected to phage therapy", Arch. Immunol Ther. Exp., 35, 553(1987)	
NK		Garrett, J. et al. "Cell lysis by induction of cloned lambda lysis genes", Mol Gen Genet (1981) 182: 326-331	

Examiner Signature	/Nicole Kinsey/	Date Considered	10/03/2006
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<p>Under the Espionage Regulations, which require the applicant and inventor to refrain from disclosing information relating to a pending or pending application, the applicant and inventor agree to refrain from disclosing information relating to the invention to any person other than the Commissioner of Patents.</p> <p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(fill in as many sheets as necessary)</i></p>				<p align="center"><b>Complete if Known</b></p>	
				Application Number	10/714,591
				Filing Date	November 14, 2003
				First Named Inventor	RAMACHANDRAN, JANAKIRAMAN
				Art Unit	1616
				Examiner Name	Not yet assigned
Sheet	2	of	2	Attorney Docket Number	GANG-006

[illegible]

Examiner Signature	/Nicole Kinsey/	Date Considered	10/03/2006
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/714,591
Filing Date	November 14, 2003
First Named Inventor	RAMACHANDRAN JANAKIRAMAN
Art Unit	1816
Examiner Name	Not Yet Assigned
Attorney Docket Number	GANG-006

**U.S. PATENT DOCUMENTS**

Examiner Initials'	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
		US	4,257,000	08/19/1988	Norris	
		US	5,698,501	11/18/1997	Merril et al.	
		US	2002/0050027	05/16/2002	Nelson et al.	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

Duplicates

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

**OTHER ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>

Examiner  
Signature

/Nicole Kinsey/

Date  
Considered

10/03/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.